Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
20 October 2023 | Story Samkelo Fetile
2023 UFS Thought-Leader Webinar Series

The University of the Free State (UFS) is pleased to present a panel discussion titled, Student protest action, politics, and higher education, which is part of the 2023 Thought-Leader Webinar Series. Join Prof Adam Habib and Dr Max Price for a discussion about their respective experiences in leadership positions during the #RhodesMustFall and #FeesMustFall student protest movements, the lessons learnt during these tumultuous times, and how these events continue to influence the current landscape in the higher education sector in South Africa and further afield. The discussion will reflect on their recent books Rebels and Rage: Reflecting on #FeesMustFall, and Statues and Storms, and will be facilitated by Prof Francis Petersen, the Vice-Chancellor and Principal of the UFS.


Date:   Tuesday 21 November 2023

Time: 13:00-14:30

Click to view document WATCH: vimeo.com/kovsies/tls23

For further information, contact Alicia Pienaar at pienaaran1@ufs.ac.za.


Some of the topics discussed by leading experts in 2022 included, Crime in South Africa – who is to blame; Are our glasses half full or half empty; What needs to be done to power up South Africa; A look into the future of South Africa. This year’s webinar series commenced with a discussion on Threats to South Africa’s stability and security challenges, followed by A culture of acceptance – is this South Africa’s greatest threat? and The need for a global and regional plan / approach to respond to the consequences of the Russia-Ukraine war.


Facilitator:

Prof Francis Petersen

Vice-Chancellor and Principal, UFS

 

Panellists:

Prof Adam Habib

Director: School of Oriental and African Studies, University of London

 

Dr Max Price

Emeritus Vice-Chancellor, University of Cape Town; academic and consultant

 

Bios of speakers:

 

Prof Adam Habib

Prof Adam Habib is an academic, researcher, activist, administrator, and well-known public intellectual. A Professor of Political Science, Prof Habib has more than 30 years of academic, research, and administration expertise, spanning five universities and multiple local and international institutions.

Prior to his appointment as Director of SOAS, he was Vice-Chancellor and Principal of the University of the Witwatersrand (Wits) in Johannesburg, South Africa between 2013 and 2020. He has also served as Deputy Vice-Chancellor of Research at the University of Johannesburg, Executive Director of Democracy and Governance at the Human Sciences Research Council, and as Director of the Centre for Civil Society and Professor of Development at the University of KwaZulu-Natal. He is widely published, including his two well-received monographs, South Africa's Suspended Revolution: Hopes and Prospects and Rebels and Rage: Reflecting on #FeesMustFall.

Prof Habib’s academic contributions resulted in his election to the American Academy of Arts and Sciences, in addition to serving as a fellow of both the African Academy of Sciences and the Academy of Science of South Africa. He also serves on the Council of the United Nations University.

 

Dr Max Price

Dr Max Price was appointed Vice-Chancellor of the University of Cape Town in July 2008, completing his ten-year term in June 2018. During the first seven years of his term, UCT experienced growth and success in research and teaching, as well as global recognition. This continued during the last three years but was overshadowed by the Rhodes Must Fall and Fees Must Fall protests during 2015 to 2017. Dr Price led the university through these storms and back to safe harbour in 2018.

Dr Price studied Medicine at the University of the Witwatersrand (Wits), during which time he became deeply involved in student politics, becoming SRC president a year after the Soweto uprising. He subsequently did a PPE degree at Oxford as a Rhodes Scholar. Following clinical work in academic and rural hospitals in South Africa, he gained a master’s degree in Community Health at the London School of Hygiene and Tropical Medicine, and then worked as an academic in the areas of health policy and economics, rural health services, and health science education.

He was dean of the Faculty of Health Sciences at Wits for ten years. He now consults in public health, higher education, strategic leadership, and advises foundations on grant making. He is currently a scholar in residence at the Atlantic Institute. He is the author of Statues and Storms: Leading through change, published in 2023.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept